GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects

Jeffrey Burgdorf, Xiao-lei Zhang, Katherine L Nicholson, Robert L Balster, J David Leander et al.

Neuropsychopharmacology • 2012

DOI PMC

Open-Field Test

behavioralratNot specified

Objective: Assessment of locomotor activity and sedative effects in an open arena environment to evaluate potential ketamine-like side effects of GLYX-13

Materials & Equipment Checklist

1 item

Gather these items before starting the experiment. Check off items as you prepare.

Equipment1

Open-field arena

Not specified • Not specified • Not specified • Not specified

Amazon

As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.

Protocol Steps

Open-field test administration

Rats were tested in open-field arena to assess locomotor activity and sedative effects following GLYX-13 or ketamine administration

Not specifiedNot specified

Note: Test was used to evaluate whether GLYX-13 exhibits sedative side effects comparable to ketamine

View evidence from paper

“GLYX-13, a novel NMDAR glycine-site functional partial agonist, produces an antidepressant-like effect without exhibiting substance abuse-related, gating, and sedative side effects of ketamine in the drug discrimination, conditioned place preference, pre-pulse inhibition and open-field tests”